Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Interest & Investment Income (2023 - 2025)

Cardiff Oncology's Interest & Investment Income history spans 9 years, with the latest figure at $612000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 22.24% year-over-year to $612000.0; the TTM value through Dec 2025 reached $3.1 million, down 4.76%, while the annual FY2025 figure was $3.1 million, 4.76% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $612000.0 at Cardiff Oncology, down from $716000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.1 million in Q3 2023 and bottomed at $612000.0 in Q4 2025.
  • The 3-year median for Interest & Investment Income is $820000.0 (2024), against an average of $843900.0.
  • The largest annual shift saw Interest & Investment Income tumbled 30.62% in 2024 before it rose 3.73% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $1.0 million in 2023, then decreased by 21.92% to $787000.0 in 2024, then decreased by 22.24% to $612000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Interest & Investment Income are $612000.0 (Q4 2025), $716000.0 (Q3 2025), and $835000.0 (Q2 2025).